In recent years, targeting immune checkpoint proteins has been shown to be an innovation for treatment of cancer and immune-related adverse events. Many checkpoint molecules have been identified on immune cells and/or tumor cells as activating receptors or inhibitory receptors. Many immune checkpoint proteins are also expressed as soluble forms in circulation, easily accessible as potential biomarker candidates.
This report covers the development of a bead-based multiplex assay for the quantitative profiling of a panel of co-inhibitory and co-stimulating immune checkpoint proteins. | 